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Accurate modeling of intratumor heterogeneity presents a bottleneck against drug testing. Flexibility in a preclinical platform is
also desirable to support assessment of different endpoints. We established the model system, OHC-NB1, from a bone marrow
metastasis from a patient diagnosed with MYCN-amplified neuroblastoma and performed whole-exome sequencing on the
source metastasis and the different models and passages during model development (monolayer cell line, 3D spheroid culture
and subcutaneous xenograft tumors propagated in mice). OHC-NB1 harbors a MYCN amplification in double minutes, 1p
deletion, 17q gain and diploid karyotype, which persisted in all models. A total of 80–540 single-nucleotide variants (SNVs)
was detected in each sample, and comparisons between the source metastasis and models identified 34 of 80 somatic SNVs to
be propagated in the models. Clonal reconstruction using the combined copy number and SNV data revealed marked clonal
heterogeneity in the originating metastasis, with four clones being reflected in the model systems. The set of OHC-NB1 models
represents 43% of somatic SNVs and 23% of the cellularity in the originating metastasis with varying clonal compositions,
indicating that heterogeneity is partially preserved in our model system.
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What’s new?
Intratumor heterogeneity is becoming an accepted feature of high-risk tumors but models reliably capturing this feature remain
elusive. Here the authors developed in vitro and in vivo neuroblastoma models from a single aspirate of a neuroblastoma bone
marrow metastasis and analyzed the germline patient background, the metastasis and the models via whole-exome
sequencing. The new OHC-NB1 model system partly reflects the genetic and clonal heterogeneity of the initial biopsy and
presents an important first step towards accurate preclinical modeling of neuroblastoma.
Introduction
Neuroblastoma, the most common extracranial solid tumor of
childhood, still accounts for 12% of cancer-related deaths in the
population under 15 years of age,1 mostly due to therapy-
resistant relapses of high-risk disease. These patients urgently
need novel targeted therapies and therapy combinations, whose
development requires extensive preclinical testing. MYCN onco-
gene amplification is the most frequent genetic aberration in
high-risk neuroblastoma (40–50%),2 typically accompanied by
1p36 deletion3 and 17q gain.4 Further genetically defined sub-
groups of high-risk neuroblastoma, each comprising 20–30% of
tumors, are characterized by activating TERT rearrangements or
ATRX mutations causing alternative lengthening of telomeres.5,6
The gene encoding the ALK receptor tyrosine kinase is the most
frequently mutated in neuroblastoma, with 9% of tumors bearing
activating mutations.7 Activating mutations in the RAS-MAPK
pathway and genes involved in epithelial-mesenchymal transition
frequently arise at relapse.8,9 These differing molecular compo-
nents of high-risk disease must be represented in models to sup-
port effective preclinical testing.
Deep sequencing on sequential solid and liquid biopsies rev-
ealed spatial and temporal genetic heterogeneity of copy-number
variations (CNVs)10–12 and ALK mutations13,14 within individual
patients. These recent findings underline the complexity of neu-
roblastoma genetics and pathogenesis, and have impact for dis-
ease monitoring and targeted therapy selection. The majority of
models currently used in neuroblastoma research are monoclo-
nal monolayer cultures established decades ago. Disease models
reflecting intratumor heterogeneity would be ideal to test thera-
peutic efficacy. Our aim was to develop a set of neuroblastoma
models derived from the same biosample to provide flexible sup-
port for different preclinical experimental designs and that is
strongly representative of the heterogeneous clonal composition
of the originating tissue.
Materials and Methods
Patient diagnosis and sample origin
A male patient, older than 18 months, had been diagnosed with
MYCN-amplified INRG stage M neuroblastoma and was treated
within the German Pediatric Oncology Group NB 2004 trial.
The primary tumor site was thoracoabdominal with metastases
detected in the bone marrow, liver and brain. The OHC-NB1
primary culture was derived from the first diagnostic bone mar-
row aspirate, which had 80% tumor cell infiltration. Parental
consent for the use of surplus biomaterial samples for research
purposes is documented within the German Pediatric Oncology
Group NB 2004 trial data.
OHC-NB1 propagation in mice
Cells suspended in 200 μl Matrigel™ (BD Biosciences, Franklin
Lakes, New Jersey, USA) were subcutaneously implanted into
the flanks of 6-week-old female CB17-SCID mice for passages
1 and 2 and into NMRI-Foxn1nu mice for passages 3–5. Tumor
size was measured with a caliper. Tumor volume was calculated
by π/6 (w1 × w2 × w2), where w1 was the largest tumor diame-
ter and w2 was the smallest tumor diameter. At each passage,
xenograft tumors (n ≥ 3 per passage) were explanted, then split
for four uses: (i) formalin fixation and paraffin embedding for
histology and immunohistochemistry (details in Supplementary
Materials and Methods), (ii) DNA isolation, (iii) fresh-frozen tis-
sue storage in liquid nitrogen and (iv) preparation of one tumor
for xenograft passaging (details in Supplementary Materials and
Methods). Experiments conformed to all local, national and
European regulatory standards and were approved by the local
ethics committee.
Cell culture
Neuroblastoma cells in the bone marrow sample were enriched via
density centrifugation through Ficoll (Biochrom, Berlin, Germany)
and cultivated in DMEM (Lonza, Basel, Switzerland), sup-
plemented with 10% fetal calf serum, 1% nonessential amino acids,
20 ng/ml recombinant EGF (PromoCell, Heidelberg, Germany)
and 20 ng/ml recombinant FGF2 (PromoCell). Cells were frozen
and stored in liquid nitrogen in 10% dimethyl sulfoxide in cell cul-
ture medium. To date, monolayer OHC-NB1 cells have been kept
in culture for up to 18 months, corresponding to over 75 passages.
BE(2)-C (RRID: CVCL_V006), CLB-GA (RRID: CVCL_9529),
GI-ME-N (RRID: CVCL_1232), IMR-32 (RRID: CV CL_0346),
IMR-5/75 (RRID: CVCL_M473), Kelly (RRID: CVCL_2092),
LAN-6 (RRID: CV CL_1363), SH-EP (RRID: CVCL_0524), SH-
SY5Y (RRID: CVCL_0019) and SK-N-FI cells (RRID:
CVCL_1702) were cultivated as described.5,15 The IMR5/75 cell
line is a subclone of the IMR-32 cell line. The BE(2)-C cell line was
purchased from the European Collection of Authenticated Cell
Cultures (ECACC, Salisbury, UK). The GI-ME-N, IMR-32,
Kelly, LAN-6 and SH-SY5Y cell lines were purchased from the
German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). The SH-EP cell line was
1032 Modeling neuroblastoma intratumor heterogeneity
Int. J. Cancer: 146, 1031–1041 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
G
en
et
ic
s
an
d
E
pi
ge
n
et
ic
s
kindly provided by the laboratory of M. Schwab
(Neuroblastoma Genomics, German Cancer Research Center
[DKFZ], Heidelberg, Germany), and the CLB-GA, IMR5/75
and SK-N-FI cell lines were kindly provided by M. Fischer
(Children’s Hospital of the University of Cologne, Cologne,
Germany). All cell lines have been authenticated using STR or
SNP profiling. Protocols for 3D spheroid propagation, qRT-
PCR-based and fluorescence-activated cell sorting-based
marker detection and routine contamination testing are sup-
plied in the Supplementary Materials and Methods.
Genomic analyses of OHC-NB1 models
The genomic composition of OHC-NBI models was characterized
using fluorescence in situ hybridization (FISH, details in Supple-
mentary Materials and Methods) and whole-exome sequencing
(WES). Libraries were prepared for WES using the Agilent Sur-
eSelect Human All Exon v6 kit (cat. No. 5190-8863) according to
the manufacturer’s instructions and sequenced in parallel in one
HiSeq 4000 lane with 100 nt paired-end reads and 50x average
coverage at the Genomics and Proteomics Core Facility of the Ger-
man Cancer Research Center (Heidelberg, Germany). Read
sequences and base quality scores were de-multiplexed and stored
in Fastq format using Illumina bcl2fastq software.16 BWA-mem17
was used to map the reads from each sample against the human
genome reference in assembly GRh37. Somatic single-nucleotide
variants (SNVs) in each model system (original bone marrow
metastasis, primary OHC-NB1 culture, xenograft passage 1 cells,
OHC-NB1 monolayer culture, xenograft passage 4 cells, condi-
tioned medium from xenograft passage 4 cells) were called with
Mutect18 using the germline sample (lymphocytes) as a control.
Variants were annotated using Jannovar19 and filtered for artifacts
from PCR or sequencing using the DKFZBiasFilter.20 To compile
all available data for the complete set (union) of variants across all
samples, the total numbers of reads supporting both the reference
and variant alleles were computed from each BAM file using a
combination of samtools mpileup and bcftools call. A smaller list of
variants predicted to affect well-known cancer genes was generated
by selecting mutations categorized as missense or nonsense vari-
ants in genes belonging to the cancer gene census list downloaded
from the COSMIC database in January 2018, release v83.21 Com-
plete variant files in VCF format were imported into the R statistics
software, and numbers of variants shared among samples were
computed. CNVs were analyzed in paired fashion using the Copy-
writeR R package22 and annotated using the CIViC database.23
Regions gained or lost that had an absolute log2 fold-change
greater than 0.3 (compared to the germline control) were
converted into standard Bed format and visualized using
CIRCOS.24 SNVs and CNVs were used to assess both clonal com-
position and evolution using the QuantumClone R package.25
SNVs with a variant allele frequency of at least 10% in at least one
sample were selected for computations, resulting in a total of
336 variants across the six samples. R statistics software was
employed for statistical tests and visualizations.26
Data availability
Raw sequencing data have been uploaded to the European
Genome-phenome Archive (accession: EGAS00001003031).
Results
OHC-NB1 serves as an in vitro and in vivo experimental
model
Here, we describe an adherent monolayer cell line, a 3D spher-
oid culture and a subcutaneous xenograft mouse model derived
from the same infiltrated bone marrow aspirate from a patient
diagnosed with INRG stage M neuroblastoma (Fig. 1). Mono-
layer OHC-NB1 cells exhibited a neuroblastic phenotype and
proliferated with a doubling time of 42 hr when cultivated in
medium supplemented with 10% fetal calf serum, epidermal
growth factor and fibroblast growth factor 2 (Figs. 2a and 2b).
In contrast, monolayer OHC-NB1 cells did not or hardly prolif-
erate when cultured in medium supplemented with B27 serum-
free supplement as a protein source or omitting the growth fac-
tors (Fig. 2c). If cultivated in Matrigel™, primary OHC-NB1
cells grew as nonadherent 3D spheroids (Fig. 2d). Primary
OHC-NB1 cells were implanted into the flanks of CB17-SCID
or NMRI-Foxn1nu mice to create the xenograft model. Serial
subcutaneous xenotransplantation through new host mice
maintained tumorigenicity with a 100% take rate throughout
five passages (Figs. 2e–2g). OHC-NB1 monolayers, 3D spher-
oids and xenografts show stable cultivation, and present a flexi-
ble system for preclinical experimental design.
OHC-NB1 cells express protein markers characteristic of
neuroblastoma
The expression of neuroblastoma marker proteins on the cell sur-
face was assessed in fluorescence-activated cell sorting-based ana-
lyses of monolayer and 3D spheroid models as proof of tumor
derivation. Neuroblastoma cells coexpress NCAM1 and GD2, a
pattern that segregates neuroblastoma from other neuro-
ectodermally derived pediatric tumors.27 L1CAM is amarkermore
widely expressed on many neuroectodermally derived tumors
including neuroblastoma.28 In monolayers, >95% of OHC-NB1
cells expressed NCAM1 and GD2 (Fig. 3a) and up to 85%
expressed L1CAM (Fig. 3a). NCAM1 and GD2 were coexpressed
in >95% of OHC-NB1 monolayer cells (Fig. 3b). L1CAM was
coexpressed with either NCAM1 or GD2 in up to ~85% of OHC-
NB1 monolayer cells (Fig. 3b). The percentage of cells dissociated
from OHC-NB1 3D spheroids that coexpressed NCAM1 and
GD2 was comparable to the monolayer model (Figs. 3c and 3d),
but the fraction expressing L1CAM was smaller (Figs. 3c and 3d).
These data show that OHC-NB1 monolayer and spheroid models
express characteristic markers for neuroblastoma.
NB84 and SYP, common markers in routine neuroblas-
toma diagnostics,29 were immunohistochemically detected in
OHC-NB1 xenograft tumors, demonstrating a representative
neuroblastoma immunohistology (Fig. 4). The expression of
druggable targets was investigated to identify signaling path-
way alterations. High levels of activated (phosphorylated)
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EGFR were detected, with enhanced levels at the tumor mar-
gins (Fig. 4). In contrast, immunohistochemistry for phos-
phorylated AKT1 or RPS6KB1 indicated no evidence of
PIK3CA/AKT1/MTOR pathway activation (Fig. 4). Actively
cycling cells express MKI67,30 which was detected in close to
100% of cells in OHC-NB1 xenografts (Fig. 4). As expected
for cells harboring wild-type TP53, only 10–15% of cells in
OHC-NB1 xenografts demonstrated transcriptionally active
nuclearly localized TP53 (Fig. 4). Expression of the CD9 cell
surface glycoprotein, which was recently identified as a sup-
pressor of the invasion-metastasis cycle in neuroblastoma,31
was below the detection limit. OHC-NB1 xenograft tumors
express characteristic neuroblastoma markers and biomarkers
indicating overactive EGFR signaling.
MYCN amplification is the leading genetic alteration in OHC-
NB1 cells
The OHC-NB1 genomic background was characterized using
FISH and WES. Multicolor FISH illuminated a diploid male
karyotype with gains at 2p and 17q and the three derivative
chromosomes, der(1)t(1;2), der(20)t(1;20) and der(16)t(16;17)
(Fig. 5a). FISH analysis with BAC probes specific for the
MYC and MYCN loci revealed two MYC copies on chromo-
some 8q, two MYCN copies on chromosome 2p and MYCN
amplification as double minutes (Fig. 5b), creating high
MYCN levels that are comparable to those in established
MYCN-amplified neuroblastoma cell lines (Fig. S1a). MYCN
amplification was associated with upregulated TERT expres-
sion as previously shown for other MYCN-amplified neuro-
blastoma cell lines and tumors (Fig. S1b).5,6 MYCN
amplifications and TERT rearrangements have been demon-
strated to be mutually exclusive in high-risk neuroblasto-
mas.5,6 Targeted sequencing excluded genomic
rearrangements proximal to TERT (data not shown), con-
firming the mutual exclusivity of MYCN amplifications and
TERT rearrangements in our model. All genomic analyses
pinpoint MYCN amplification as the leading genetic aberra-
tion in OHC-NB1.
OHC-NB1 partially reflects the heterogeneity of the
originating metastasis
To understand how well each model reflects the source metas-
tasis and track the dynamics of genetic heterogeneity in the
model system, WES was performed on the source bone mar-
row metastasis and lymphocytes (as a germline control) from
the patient as well as different OHC-NB1 culture models and
passages during model development. The OHC-NB1 primary
culture, xenograft passage 1, the monolayer model and the cel-
lular fraction and medium conditioned by the intermittent
in vitro culture of xenograft passage 4 were sequenced. CNV
analysis identified a 1p deletion terminal to 1p22.3, 17q gain
and MYCN amplification, all of which remained stable
bone marrow 
aspirate
primary culture 3D spheroids
2D monolayer
xenografts
in serial transplantation
Figure 1. Schematic overview of OHC-NB1 models. The monolayer, spheroid and patient-derived xenograft models were all established from
the same infiltrated bone marrow aspirate from a patient diagnosed with INRG stage M (metastasized) neuroblastoma.
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throughout all model systems (Fig. 5c). SNV analysis consid-
ered all SNVs, regardless of their potential effect on the pro-
tein coding sequence. A total of 80–540 (median: 153) SNVs
were detected in each sample (Fig. 6a), of which the large
majority were bona fide somatic SNVs since <5.4% of the
identified SNVs were listed in databases compiled by large-
scale sequencing efforts in healthy individuals (Table S2).
Comparisons between the source metastasis and models iden-
tified 34 of 80 somatic SNVs to be propagated in the models
(Fig. 6a), with 20 SNVs detected in all models and 14 detected
in at least one model. The remaining 46 somatic SNVs present
in the source metastasis were not represented in the models
(Fig. 6a). SNVs specific to a model comprised 26% of SNVs in
the primary culture and 46% in the monolayer model
(Fig. 6a). Many specific SNVs were detected in xenograft pas-
sage 1 that were not propagated in later xenograft passages
(Fig. 6a) and most likely represent one or more clones present
only in xenograft passage 1 (Fig. 6c). We detected 34 SNVs in
all models but not the source metastasis (Fig. 6b) that either
arose in the primary culture or were below detection sensitiv-
ity in the source metastasis. Another eight SNVs identified in
the source metastasis were detected in one or more models
but not the primary culture (Fig. 6b). This heterogeneity
extended to nonsilent mutations in known cancer genes
(Fig. S2). Deleterious mutations in KAT6B, KDM6A and
NOTCH2 are prominent but specific to the xenografts, while a
mutation in LSM14A is present in the source bone marrow
metastasis and xenograft samples, yet absent in other cultures
(Fig. S2). Taken together, an MYCN amplification, 1p dele-
tion, 17q gain and small SNV set were propagated from the
originating metastasis through all OHC-NB1 models. Other
SNVs harbored in the source metastasis were propagated in at
least one model, indicating clonal heterogeneity is partially
preserved in our model system.
To understand and compare the clonal composition of
the source metastasis to those of the model systems, we
assessed clonal composition in each sample and carried out
clonal reconstruction using the combined CNV and SNV
data. Marked clonal heterogeneity existed in the originating
metastasis, with four clones (accounting for 23% of cellular-
ity in the metastasis) being reflected in the model systems
(Fig. 6c). The remaining 77% of cellularity in the source
metastasis was lost after propagation. Clone #3, characterized
by 72 SNVs, made up <10% of the originating metastasis,
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Figure 2. OHC-NB1 cells can be propagated in vitro and serially passaged as subcutaneous xenografts in mice. (a) Representative phase-
contrast micrograph of OHC-NB1 monolayer model, passage 10. 200× magnification. (b) Growth curve for OHC-NB1 monolayer model in
passage 14. (c) Comparison of OHC-NB1 monolayer cell numbers under different culture conditions. In total, 10 × 104 cells were seeded
(dotted line), and cell numbers were measured by semiautomated trypan blue staining 168 hr later. (d) Representative phase-contrast image
of OHC-NB1 3D spheroid model. 10× magnification. (e) Growth curves for five serial passages (P) of OHC-NB1 cells as subcutaneous
xenografts in CB17-SCID mice (P1 and P2) and NMRI-Foxn1nu mice (P3–P5). Engraftment of all tumors (n = 25) in serial transplantation
(n = 5) is shown (mean  SEM). Subcutaneous xenograft tumor in a representative mouse are shown (f ) before and (g) after preparation.
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but underwent substantial clonal expansion before becoming
the dominant clone in all models (Fig. 6c). Clone #5 was
solely present in xenograft passage 1, and accounted for the
large number of specific mutations in that sample (Figs. 6a
and 6c). The other three clones present in the originating
metastasis made up elevated fractions of tumor cells in the
xenograft and monolayer models (Fig. 6c). Taken together,
the models represent 43% of somatic SNVs and 23% of the
cellularity in the originating metastasis, with varying clonal
compositions.
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Figure 3. OHC-NB1 cells coexpress common neuroblastoma cell surface markers. (a) Fluorescence-activated cell sorting-based detection of
NCAM1, GD2 and L1CAM expression in OHC-NB1 2D monolayer model shown as single-parameter histograms. (b) Representative dot plots of
costained OHC-NB1 2D monolayer model cells. Neuroblastoma marker expression in the OHC-NB1 (c) 2D monolayer model and (d) 3D
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(NCAM1/GD2, L1CAM/NCAM1, L1CAM/GD2) is presented as the arithmetic mean  SD in bar graphs.
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Targeted transcript expression analysis and
phosphoproteomics reveal commonalities among the set of
OHC-NB1 models
To investigate potential differences at the transcriptional level
across the set of OHC-NB1 models and how they compare to
established neuroblastoma cell lines, relative quantitative
expression of MYCN, LIN28B, TERT, BIRC5, HDAC5,
NTRK2, DCX, GAP43, NEFL and NES was assessed by qRT-
PCR. The genes selected for targeted transcript expression
analysis are oncogenic drivers in neuroblastoma (MYCN,
LIN28B, TERT), MYCN targets (BIRC5, HDAC5) or play a
role in neuroblastoma cell differentiation and stemness
(NTRK2, DCX, GAP43, NEFL, NES). All 10 genes were simi-
larly expressed in the primary culture, xenograft passages #1
and #4 as well as in the 3D spheroids and the 2D monolayer
(Fig. S3). The overall expression pattern of OHC-NB1 most
closely resembled the two MYCN-amplified neuroblastoma
cell lines BE(2)-C and Kelly (Fig. S3). We performed a cus-
tomized Luminex assay to compare protein phosphorylation
in the PI3K/AKT and MEK/ERK signaling pathways among
the primary OHC-NB1 culture, 2D monolayer and 3D spher-
oids. Phosphorylation levels in the primary culture and 3D
spheroids resembled each other more than those measured in
the 2D monolayer, underlining the importance of exploiting
the potential of 3D in vitro culture systems in future studies
(Fig. S4). In summary, the mRNA and targeted phospho-
proteome data presented here support the unbiased analysis
of the set of OHC-NB1 models at the transcriptional and
posttranslational level by OMICS technologies within the
framework of a new study.
Discussion
Large-scale sequencing provided evidence of intratumor het-
erogeneity in the adherent OHC-NB1 monolayer model, a 3D
spheroid model and serially transplantable xenograft tumor
model in mice, which were all established from the same
metastasis from an MYCN-amplified INRG stage M neuro-
blastoma (summarized as a model in Fig. S5). Capturing the
landscape of spatial and intratumor heterogeneity in solid
tumors has major implications for our understanding of
Figure 4. Expression of common neuroblastoma marker and druggable target proteins in OHC-NB1 xenografts. Representative micrographs
are shown for OHC-NB1 xenograft model (passage 2) histology (HE: hematoxylin/eosin staining) and immunohistochemistry detecting the
common neuroblastoma markers, NB84 (a 57 kD uncharacterized molecule used as a marker in routine pathology) and synaptophysin (SYP);
the phosphorylated (activated) forms of the signaling proteins, epidermal growth factor receptor (EGFR), AKT serine/threonine kinase 1 (AKT1)
and ribosomal protein S6 kinase B1 (RPS6KB1), in addition to the marker of proliferation Ki-67 (MKI67), subcellular localization of the tumor
protein p53 (TP53) and expression of the transmembrane four superfamily member CD9 molecule (CD9). 630× magnification.
Thole et al. 1037
Int. J. Cancer: 146, 1031–1041 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
G
en
et
ic
s
an
d
E
pi
ge
n
et
ic
s
Figure 5. Genome-wide analysis of structural aberrations and CNVs in the OHC-NB1 model. (a) Representative multicolor FISH karyotype of the OHC-
NB1 2D monolayer model employing three marker (mar) chromosomes, mar1 t(1;2), mar2 t(1;20) and mar3 t(16;17). (b) FISH-based detection of
MYCN (green, BAC clone RP11-355H10) and MYC (red, BAC clone CTD-2034C18) in a chromosomal spread (stained with DAPI to detect DNA, blue)
from the OHC-NB1 2D monolayer model, demonstrating extrachromosomal copies of the MYCN locus in the form of double minutes and a diploid
complement of the MYC locus. (c) Circos plot reconstructed from whole-genome sequencing data and displaying CNVs in the originating bone marrow
metastasis and different OHC-NB1 models or stages of OHC-NB1 model development. Xenograft #1, OHC-NB1 xenograft model passage 1; xenograft
#4, OHC-NB1 xenograft model passage 4; conditioned medium, medium conditioned by the intermittent in vitro culture of xenograft passage 4.
1038 Modeling neuroblastoma intratumor heterogeneity
Int. J. Cancer: 146, 1031–1041 (2020) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf
of UICC
C
an
ce
r
G
en
et
ic
s
an
d
E
pi
ge
n
et
ic
s
cancer pathogenesis and progression as well as clinical
decision-making towards targeted therapeutics in mono or
combination therapy approaches. Different approaches
employing chromosomal aberrations and breakpoints as well
as CNVs and SNVs have been developed to reconstruct the
clonal composition of solid tumors.10,24 Clonal reconstruc-
tions of multiregion sequencing from the same renal cell
carcinoma,32 high-grade glioma,33 medulloblastoma34 or
breast cancer35 revealed high-level spatial heterogeneity with
individual samples having different dominant clones. Here, we
demonstrate the preservation of clonal heterogeneity in the
flexible patient-near OHC-NB1 neuroblastoma model system.
As intratumor genetic heterogeneity and clonal evolution
have established as the normal situation in high-risk disease
rather than the exception, the need for preclinical models
recapitulating these traits has become more apparent. Publi-
shed sequencing data of matching pairs of models and the
originating tissue are rare. In glioblastoma, a study of 10 mat-
ched pairs of cell lines and their source tumors reported an
average overlap of 41% of somatic SNVs.36 A comparison of
ALK mutations in 2 cell lines and their originating neuroblas-
toma samples revealed that the oncogenic F1174L mutation
was ubiquitous in all cells of both cell lines, but was detected
in only 0.03% and 6.6% of cells in the originating tissues, indi-
cating the ALK mutation provided selection pressure for the
subclone in monolayer culture.14 Another study applied
whole-genome sequencing and array-based comparative geno-
mic hybridization to compare eight neuroblastoma cell lines
with the six primary tumors and two bone marrow metastases
from which they were derived.37 While MYCN amplification,
17q gain and 1p36 deletion were stably propagated in the cell
lines, shorter CNAs differed between the cell lines and their
origins, and were interpreted as potential subclonal events that
were below the detection limit in the primary tumor.37 The
Figure 6. OHC-NB1 models partially reflect the heterogeneity of the originating metastasis. (a) Bar graphs of somatic SNVs in the originating
bone marrow metastasis, different OHC-NB1 models or stages of OHC-NB1 model development. SNVs are categorized as occurring only in the
sample indicated (specific), occurring in all samples (ubiquitous) or occurring in >50% or <50% of samples. (b) Heatmap of somatic SNVs
shared by at least two samples. Frequency of SNV detection in each sample is indicated with the blue color gradient. (c) Clonal
reconstruction of sample of origin and models. Each sample is displayed as a stacked column, with individual contributing clone proportions
displayed by the different stacked colors in the column (stack height indicates the percentage of each clone in the model). Xenograft #1,
OHC-NB1 xenograft model passage 1; xenograft #4, OHC-NB1 xenograft model passage 4; conditioned medium, medium conditioned by the
intermittent in vitro culture of xenograft passage 4.
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OHC-NB1 model system presented here belongs to the first
model systems capturing intratumor heterogeneity and clonal
evolution for high-risk neuroblastoma. WES of the originating
bone marrow metastasis and different OHC-NB1 models rev-
ealed clonal heterogeneity in the originating metastasis, reca-
pitulation of this clonal heterogeneity in the model systems
and further clonal evolution during model propagation. While
most clones are shared between the originating bone marrow
metastasis and models, the models differ considerably with
respect to which clone(s) became dominant. These clones are
also marked by nonsilent mutations in known cancer-relevant
genes, which may act as secondary tumor driver events.
Together, the different OHC-NB1 models reflect a heteroge-
neous tumor disease, in which cell clones have variable growth
rates and, potentially, varying responses to therapy. The
OHC-NB1 model only represents 43% of somatic SNVs and
23% of the cellularity in the source metastasis, indicating that
only a subset of the neuroblastoma cells that metastasized to
the bone marrow niche could be successfully propagated
under the selected experimental conditions. This observation
underlines the importance of further optimizing experimental
workflows to fully capture the complexity of high-risk neuro-
blastoma in experimental models. Orthotopically xenografting
patient samples may present an interesting alternative
approach. Recently, orthotopically implanted patient-derived
neuroblastoma and medulloblastoma xenografts were reported
to maintain genetic, epigenetic, transcriptional and phenotypic
stability and reflect aspects of spatial intratumor heterogene-
ity.38,39 Generating (orthotopic) neuroblastoma patient-
derived xenografts in mice is very useful, but does not support
high-throughput screening and continues to be inefficient,
despite the use of the most recent implantation strategies, for
a subset of neuroblastomas that include tumors lacking
MYCN amplifications or TERT alterations. Establishing neu-
roblastoma organoids from fresh samples may, therefore, rep-
resent a third preclinical neuroblastoma model, situated
between the in vitro 2D cell lines and the in vivo PDX models.
Organoids are 3D models of primary tumor tissue obtained
from fresh biopsies, which are generated by partial mechanical
or enzymatic digestion before embedding the resulting small
tumor pieces in an extracellular matrix, such as Matrigel.
Recently, 3D organoids were shown to be propagated in Mat-
rigel from various cancer types, including breast,40 colon,41
pancreatic,42 ovarian43 and prostate cancers.44 While success
rates of organoid establishment clearly appear to vary by
tumor grade and cancer type, several studies reported that
tumor-derived 3D-organoids propagated in Matrigel retain
the histological and genetic features of the originating tumors
and recapitulate drug responses observed in matched
patients.40,45 A shortcoming of classical cancer organoid cul-
tures is the lack of stroma, blood vessels and immune cells.
More recently, coculture systems have incorporated cancer-
associated fibroblasts into pancreatic cancer organoids and
matched tumor-derived peripheral blood lymphocytes into
colon and non-small cell lung cancer organoids.46,47 Organoid
culture systems are, however, more costly than 2D cultures,
due to the need for extracellular matrix. Here, we show that
establishing OHC-NB1 neuroblastoma spheroids, as defined
by spherical aggregates of tumor cells that originate from a
tiny clinical bone marrow sample containing metastatic neu-
roblastoma cells, is technically feasible.
Intratumor heterogeneity is becoming accepted as a char-
acteristic feature of high-risk tumors. Its implications for bio-
marker discovery, drug target identification, drug response,
treatment decisions and resistance development make models
reliably capturing intratumor heterogeneity highly valuable for
preclinical drug evaluation in addition to their more
encompassing recapitulation of the multiple clonal and genetic
aspects of the disease. The trinity of OHC-NB1 models pres-
ented here partly reflects the genetic and clonal heterogeneity
of high-risk metastatic neuroblastoma to support an accurate
preclinical modeling of neuroblastoma.
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